GlassScriptPhysician profile
Bethanie Muraski
NPI 1952960643
$12,635.01
in general payments reported to CMS, 2019-2025
44 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,083 · 2022: $2,752 · 2023: $2,859 · 2024: $2,694 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,750 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,749.86 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,719.21 | 2021-2025 | |
| Novo Nordisk INC | $1,824.91 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $1,172.66 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $762.87 | 2021-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $665.95 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $618.18 | 2021-2025 | Ajovy, Austedo Xr |
| Pfizer INC. | $518.58 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $390.87 | 2021-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $378.37 | 2021-2024 | Xarelto |
| Amgen INC. | $361.40 | 2021-2024 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $348.60 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $332.63 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $325.28 | 2021-2025 | Wellbutrin, Aplenzin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.56 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $185.49 | 2023-2025 | Cologuard Collection Kit |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethanie Muraski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.